Medical therapy of inflammatory bowel diseases: Ulcerative colitis;A gyulladásos bélbetegségek gyógyszeres kezelése: Colitis ulcerosa

Orvosi Hetilap

Volumn 148, Issue 25, 2007, Pages 1163-1170

  Lakatos, László ^a,c   Lakatos, Péter László ^b  

^a Veszprém Megyei Csolnoky Ferenc Egyetemi Oktató Kórház   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c NONE   (Hungary)

Author keywords

5 ASA; Azathioprine; IBD; Infliximab; Therapy; UC

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CYCLOSPORIN; EUDRAGIT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; OLSALAZINE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG; XALAZIN; CORTICOSTEROID; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; COLITIS; COLON RESECTION; COLORECTAL CANCER; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENTERITIS; HUMAN; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PROCTITIS; REVIEW; ULCERATIVE COLITIS; CARCINOMA; COLORECTAL TUMOR; HOSPITALIZATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CARCINOMA; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CYCLOSPORINE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MESALAMINE; SEVERITY OF ILLNESS INDEX;

EID: 34548276532     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2007.28063     Document Type: Review

References (50)

1. Kornbluth, A., Sachar, D. B.: Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol., 2004, 99, 1371-1385.
2. Carter, M. J., Lobo, A. J., Travis, S. P. I. és mtsai: Guidelines for the management of inflammatory bowel disease in adults. Gut, 2004, 53(Suppl. V.), v1-v16.
3. Sutherland, L., MacDonald, J. K.: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2006, 2 CD000543.
4. Ransford, R. A. J., Langman, M. J. S.: Sulfasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut, 2002, 51, 536-539.
5. Hanauer, S. B.: Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment. Pharmacol. Ther., 2006, 24(Suppl.3.), 37-40.
6. Hanauer, S. B., Schwartz, J., Bobinsom, M. és mtsai: Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am. J. Gastroenterol., 1993, 88, 1188-1197.
7. Hanauer, S. B., Sandborn, W. J., Kornbluth, A. és mtsai: Delayed-release oral mesalamine at 4,8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND trial. Am. J. Gastroenterol., 2005, 100, 2478-2485.
8. Kruis, W., Bar-Meir, S., Fehér J. és mtsai, for the International Salofalk Pellets Study Group: The optimal dose of 5-aminosalicylic-acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin. Gastroenterol. Hepatol., 2003, 1, 36-43.
9. Marteau, P., Probert, C. S., Lindgren, S. és mtsai: Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut, 2005, 54, 960-965.
10. Cohen, R. D., Woseth, D. M., Thisted, R. A. és mtsai: A meta-analysis an overview of the literature of treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am. J. Gastroenterol., 2000, 95, 1263-1276.
11. Hanauer, S. B.: Dose-ranging study of mesalamine (PENTASA) enema in the treatment of acute ulcerative proctosigmoiditis: results of a multicenter, placebo-controlled trial. The U. S. PENTASA Enema Study Group. Inflamm. Bowel. Dis., 1998, 4, 79-83.
12. Gionchetti, P., Rizzello, F., Morselli, C. és mtsai: Review article: aminosalicylates for distal colitis. Aliment. Pharmacol. Ther., 2006, 24 (Suppl. 3), 41-44.
13. Bergman, R., Parkes, M.: Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment. Pharmacol. Ther., 2006, 23, 841-855.
14. Marshall, J. K., Irvine, E. J.: Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am. J. Gastroenterol., 2000, 95, 1628-1636.
15. Moody, G. A., Eaden, J. A., Helyes Z. és mtsai: Oral or rectal administration of drugs in IBD? Aliment. Pharmacol. Ther., 1997, 11, 999-1000.
16. Safdi, M. A., DeMicco, M., Sninsky, C. és mtsai: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol., 1997, 92, 1867-1872.
17. Mulder, C. J., Fockens, P., Meijer, P. W. és mtsai: Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur. J. Gastroenterol. Hepatol., 1996, 8, 549-553.
18. Domenech, E.: Inflammatory bowel disease: current therapeutic options. Digestion, 2006, 73(Suppl.), 67-76.
19. Hanauer, S. B.: Medical therapy for ulcerative colitis 2004. Gastroenterology, 2004, 126, 1582-1592.
20. Löfberg, R., Danielsson, A., Suhr, O. és mtsai: The Mesalamine Study Group. Oral bodesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology, 1996, 110, 1713-1718.
21. Chapman, R. W., Selby, W. S., Jewell, D. P.: Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in ulcerative colitis. Gut, 1986, 27, 1210-1212.
22. Rosenberg, W., Ireland, A., Jewell, D.: High-dose metilpred-nisolone in the treatment of active ulcerative colitis. J. Clin. Gastroenterol., 1990, 12, 40-41.
23. McIntyre, D. B., Powell-Tuck, J., Wood, S. R.: Controlled trial of bowel rest in the treatment of severe acute colitis. Gut, 1986, 27, 481-485.
24. Lichtiger, S., Present, D. H., Kornbluth, A. és mtsai: Cyclosporine in severe ulcerative colitis, refractory to steroid therapy. N. Engl. J. Med., 1994, 330, 1841-1845.
25. Van Assche, G., D'Haens, G., Noman, M. és mtsai: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosoprine in severe ulcerative colitis. Gastroenterology, 2003, 125, 1025-1031.
26. Shibolet, O., Regushevskaya, E., Brezis, M. és mtsa: Cyclosporin A for induction of remission in severe ulcerative colitis. Cochran Database Syst. Rev., 2005, 1, CD004277.
27. Rutgeerts, P., Sandborn, W. J., Feagan, B. G. és mtsai: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 353, 2462-2476.
28. Lawson, M. M, Thomas, A. G., Akobeng, A. K.: Tumor necrosis factor alpha blocking agents for inducing remission in ulcerative colitis. Cochran Database Syst. Rev., 2006, 3, CD0005112.
29. Jarnerot, G., Hertervig, E., Friis-Liby, I. és mtsai: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology, 2005, 128, 1805-1811.
30. Fraser, A. G., Orchard, T. R., Jewell, D. P.: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut, 2002, 50, 485-489.
31. Ardizzone, S., Maconi, G., Russo, A. és mtsai: Randomised controlled trial of azathioprine and 5-aminosaliocylic acid for treatment of steroid dependent ulcerative colitis. Gut, 2006, 55, 47-53.
32. Siegel, C. A., Sands, B. E.: Review article: practical management of inflammatory bowel disease patients taking immunmodulators. Aliment. Pharmacol. Ther., 2005, 22, 1-16.
33. Kandiel, A., Fraser, A. G., Korelitz, B. I. és mtsai: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut, 2005, 54, 1121-1125.
34. Schröder, O., Stein, J.: Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am. J. Gastroenterol., 2003, 98, 530-537.
35. De Saussure, P., Soravia, C., Morel, P. és mtsa: Low-dose oral microemulsion cyclosporin for severe, refractory ulcerative colitis. Aliment. Pharmacol. Ther., 2005, 22, 203-208.
36. Orchard, T., Probert, C. S., Ceshav, S.: Review article: maintenance therapy in patients with ulcerative colitis. Aliment. Pharmacol. Ther., 2006, 24(Suppl. 1), 17-22.
37. Sutherland, L., MacDonald, J. K.: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2006, 2, CD000544.
38. Fockens, P., Mulder, C. J., Tytgat, G. N. és mtsai: Comparison of the efficacy and safety of 1.5 g compared with 3.0 g oral, slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur. J. Gastroenterol. Hepatol., 1995, 7, 1025-1030.
39. Maakhouski, Y., Fixa, B., Holoman, J. és mtsai: A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment. Pharmacol. Ther., 2005, 21, 133-140.
40. Frieri, G., Pimo, M., Galletti, B. és mtsai: Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig. Liver. Dis., 2005, 37, 92-97.
41. Piodl, L. P., Ulivieri, F. M., Cermesoni, L. és mtsa: Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand. J. Gastroenterol., 2004, 39, 154-157.
42. Hawthorne, A. B., Logan, R. F. A., Hawkey, C. J. és mtsai: Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ, 1992, 305, 20-22.
43. Mantzaris, G. J., Sfakianakis, M., Archavlis, E. és mtsai: A prospective randomized, observer-blind 2-year trial of azathioprine-monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am. J. Gastroenterol., 2004, 99, 1122-1128.
44. Actis, G., C., Lagget, M., Rizzetto, M. és mtsai: Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis. Minerva Med., 2005, 95, 65-70.
45. Lobel, E. Z., Korelitz, B. I., Xuereb, M. A. és mtsa: A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am. J. Gastroenterol., 2004, 99, 462-465.
46. Stange, E. F.: Review article: the effect of aminosalicylates and immunmodulation on cancer risk in inflammatory bowel disease. Aliment. Pharmacol. Ther., 2006, 24, 64-67.
47. Lakatos L., Mester G., Erdélyi Z. és mtsai: Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm. Bowel. Dis., 2006, 12, 205-11.
48. Kruis, W., Fris, P., Pokrotnieks, J. és mtsai: Maintaining remission in ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazin. Gut, 2004, 53, 1617-1623.
49. Summers, R. W., Elliott, D. E., Urban, J. F.: Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology, 2005, 128, 825-832.
50. Sewitch, M. J., Abramowitz, M., Barkun, A. és mtsai: Patient nonadherence to medication in inflammatory bowel disease. Am. J. Gastroenterol., 2003, 98, 1535-1544.